USPTO issues patents to Biodesix blood-based oncology tests
In particular, the patents cover the selection of NSCLC patients for treatment with antibodies directed against the epidermal growth-factor receptor (EGFR) pathway. The patents also cover the selection
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.